The aPL profile in the APS group showed that 28 (87.5%) presented with lupus anticoagulant (LAC), 12 (37.5%) with LAC plus anti-beta 2 glycoprotein I, 7 (21.9%) with anticardiolipin (aCL), and 8 (25.0%) were triple positive (Table S2). This evidence concerns the gene ACLY and autoimmune polyendocrinopathy.